Barnbrock, AnkeAnkeBarnbrockMöricke, AnjaAnjaMörickeBarbaric, DragaDragaBarbaricJones, NeilNeilJonesKönig, ChristaChristaKönig0000-0002-9965-5183Moser, ReinhardReinhardMoserRohde, MariusMariusRohdeSalvador, ChristinaChristinaSalvadorAlten, JuliaJuliaAltenElitzur, SarahSarahElitzurGroll, Andreas HAndreas HGrollLehrnbecher, ThomasThomasLehrnbecher2024-10-262024-10-262024-06https://boris-portal.unibe.ch/handle/20.500.12422/175909Pneumocystis jirovecii can cause life-threatening pneumonia (PjP), and patients with haematological malignancies are at high risk of this infection. Prophylactic measures have significantly decreased morbidity and mortality, but there is a paucity of contemporary data on the incidence and clinical course of PjP in well-defined and homogenous patient populations, such as children suffering from acute lymphoblastic leukaemia (ALL). In the multi-international trial AIEOP-BFM ALL2009, PjP was diagnosed in six children (incidence 1/1000) and was associated with insufficient prophylaxis in five of them. Although none of the patients died of PjP, the long-term impact of the infection is unclear.enPneumocystis jirovecii acute lymphoblastic leukaemia child prophylaxis therapy600 - Technology::610 - Medicine & healtharticle10.48350/1948383852795410.1111/bjh.19382